Content area
Full Text
Flexion Therapeutics (NASDAQ:FLXN) was upgraded by ValuEngine from a "hold" rating to a "buy" rating in a research note issued on Friday.
FLXN has been the subject of several other reports. BidaskClub lowered shares of Flexion Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Tuesday, October 30th. Zacks Investment Research lowered shares of Flexion Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, August 13th. Finally, Wells Fargo & Co reiterated a "buy" rating on shares of Flexion Therapeutics in a research note on Monday, November 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Flexion Therapeutics has a consensus rating of "Buy" and a consensus target price of $36.20.
Shares of Flexion Therapeutics stock opened at $16.86 on Friday. The company has a current ratio of 8.88, a quick ratio of 8.74 and a debt-to-equity ratio of 1.02. Flexion Therapeutics has a 1 year low of $13.36 and a 1 year high of $29.10.
Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of...